Cezar MBA - Vaxart Pres CEO

Vaxart Management Efficiency

The company has return on total asset (ROA) of (0.3968) % which means that it has lost $0.3968 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9166) %, meaning that it created substantial loss on money invested by shareholders. Vaxart's management efficiency ratios could be used to measure how well Vaxart manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -0.94 in 2024. Return On Capital Employed is likely to gain to -1.01 in 2024. At this time, Vaxart's Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 150.6 M in 2024, whereas Non Current Liabilities Other is likely to drop slightly above 2.8 M in 2024.

Similar Executives

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company is headquartered in South San Francisco, California. Vaxart operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 110 people. Vaxart Inc (VXRT) is traded on NASDAQ Exchange in USA. It is located in 170 Harbor Way, South San Francisco, CA, United States, 94080 and employs 109 people. Vaxart is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Vaxart Inc Leadership Team

Vaxart Stock Performance Indicators

Additional Tools for Vaxart Stock Analysis